| HOME >> BIOLOGY >> TECHNOLOGY |
Amortization of intangibles 8,488 8,488 33,950 33,950
Total costs and expenses 148,524 163,168 551,372 573,591
Income (loss) from operations 32,666 (23,030) (23,847) (86,761)
Other income (expense):
Investment income, net 10,753 14,936 48,810 30,973
Interest expense (2,358) (3,134) (10,054) (11,068)
Other income (Note 3) - 19,500 - 22,903
Net income (loss) $41,061 $8,272 $14,909 $(43,953)
Amounts per common share:
Earnings per share, basic and
diluted (Note 4) $0.13 $0.03 $0.05 $(0.14)
Weighted average shares,
basic 320,089 315,481 318,221 313,724
Weighted average shares,
diluted 340,668 318,468 321,320 313,724
(1) In accordance with SFAS 123R, stock-based compensation expense is
allocated between research and development and selling, general and
administrative expense as follows:
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Research and development $2,439 $5,345 $10,674 $23,280
Selling, general and
administrative 3,736 4,570 14,484 18,861
(2) Certain prior year amounts have been reclassified between research and development and selling, general and administrative expenses to conform to the current year presentation. This reclassification has no impact on previously reported results.
(3) During the year ended December 31, 2006, the Company recognized a
$3.4 million deferred gain from the sale of assets to
'/>"/>
| SOURCE Millennium Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |